Fangzhou Honored as a Top Growth Stock in Hong Kong at China Capital Market Forum 2025
SHANGHAI, Sept. 18, 2025 — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a prominent provider of AI-powered Internet healthcare solutions, was honored as an “Outstanding Growth Story in Hong Kong Stocks” at the China Capital Market Development Forum, organized by ChinaFund and held in Shanghai from September 16–17.
This award acknowledges Hong Kong-listed companies demonstrating exceptional achievements in technological innovation, profit growth, and industry influence, reflecting confidence in Fangzhou’s robust operations and ongoing innovation.
Fangzhou Named ‘Outstanding Growth Case in Hong Kong Stocks’
Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, stated that this award validates their innovative strength and growth, emphasizing the recognition of AI’s value in chronic disease management.
Fangzhou’s 2025 interim results revealed revenue of RMB 1.5 billion, a 12.9% increase year-over-year. Net profit reached RMB 12.5 million, achieving profitability for the period, while adjusted net profit rose 16.8% to a record high of RMB 17.6 million. The platform’s registered user base expanded by 15.8% to 52.8 million, with 11.9 million monthly active users, a 34.4% year-over-year increase. The number of registered doctors reached 229,000, and the paid user repurchase rate was 85.4%. Its drug catalog SKU grew to 216,000, supported by partnerships with over 1,650 suppliers and 980 pharmaceutical firms.
Earlier in September, at its 10th H2H Healthcare Ecosystem Conference in Shanghai, Fangzhou launched its proprietary “XingShi” Large Language Model (“XS LLM”), an AI system designed to improve service efficiency, enhance personalization, and optimize physicians’ time in chronic disease management.
The XS LLM incorporates multimodal capabilities, including image and speech recognition, natural language processing, extensive medical knowledge storage, and reasoning, achieving advanced performance benchmarks in medical AI. This system supports five domain-specific intelligent agents: “AI Knowledge Agent”, “AI Guidance Agent”, “AI Pre-Consult Agent”, “AI Doctor Assistant”, and “AI-Electronic Medical Record (EMR) Agent”. These agents collectively create a comprehensive service architecture covering the entire lifecycle of chronic disease management.
Functioning as the “core digital brain” of Fangzhou’s platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search.
During the conference, Fangzhou also announced strategic partnerships with Innovent Biologics and Zhejiang Otsuka Pharmaceutical to collaboratively advance digital health management. Fangzhou will utilize its expertise in AI technology and platform operations to develop new digital health collaboration models with partners, contributing to the “Healthy China 2030” initiative.
About China Capital Market Development Forum
The forum, hosted by ChinaFund, gathered nearly 1,000 representatives from regulators, industry, and investment sectors to discuss new pathways and opportunities within China’s capital markets.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025. The Company specializes in providing customized medical care and AI-driven precision medicine solutions. For more details, please visit .
Media Contact
For additional information or interview requests, please contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release includes forward-looking statements. Actual results may be impacted by various factors and may differ significantly from those projected. Readers should exercise caution and avoid placing excessive reliance on these statements.
